Sep 29, 2017

GWJ RL #16: How much of what you read today will you still care about a year from now?

By Jordan Thibodeau • Issue #16 • View online

Hey Everyone,I hope you all had a great week.

The following question really hits home for me: How much of what you read today will you still care about a year from now? It’s very easy to get caught up reading current events, but how much of that news has a sell by date? Meaning our you just collecting worthless data points or are you reading things that help you see the world from different angles? Our first read goes into this. Ask yourself that question, and look at what you have consumed for information during the last week. What percentage of information have you consumed that has a sell by date? If it turns out greater than 50%, what can you do to lower that number?

Thanks to you all for joining our reading list. You probably know someone in your group that can benefit from our reading list, feel free to share our list with them or better yet ask them to subscribe! :)

As always, if you came across any good reads this week, send them my way.Always Be Learning,

Jordan

Read

Expiring vs. Long-Term Knowledge · Collaborative Fund (Reading Time: 5 Minutes)

How much of what you read today will you still care about a year from now? 80%? Half? Any of it? I ask myself this question a lot, and it’s painful. If I’m honest with myself the answer is often close to none. The Intelligent Investor by Ben Graham was written in 1934. I’ve confirmed that, eighty-three years later, it still sells more than 100,000 copies per year. It still sells because its message is timeless.

www.collaborativefund.com • Share

The Century of Biology – Andreessen Horowitz (Reading Time: 19 Minutes)

Editor’s Note: Jorge Conde is Andreessen Horowitz’ newest general partner on our bio fund, which was formally established two years ago with general partner Vijay Pande to lead the firm’s investments at the cross section of biology, computer science, and healthcare. Before joining a16z, Conde was at Syros Pharmaceuticals — where he most recently served as Chief Strategy Officer (and before that, as CFO and Chief Product Officer) — advancing a new wave of medicines to treat cancer and other diseases through a novel gene control platform. He also co-founded, with renowned Harvard and MIT genetics professor George Church, genomics interpretation company Knome (acquired by Tute Genomics in 2015). With degrees in both business and biology, Conde has also worked in marketing, operations, and, biotech investment banking. Currently based in Boston, he will soon move to California.

a16z.com • Share

Can Our Democracy Survive Tribalism? (Reading Time: 45 Minutes)

Tribalism was an urge our Founding Fathers assumed we could overcome. And so it has become our greatest vulnerability.

nymag.com • Share

Listen

Here's One Big Reason Tesla Still Doesn't Dominate Our Roads - Bloomberg

Can a national network of charging stations convince Americans to finally drive electric cars?

www.bloomberg.com • Share

Thanks for reading this weeks reading list

If you like what you read and you want it delivered to your inbox subscribe to my newsletter or share it with your friends. Also, you can find last week’s reading list here. If you have any articles I should check out, please email me at jt@growwithjordan.com

Did you enjoy this issue?

By Jordan Thibodeau

This list has been deprecated, you can find the new list here: www.getrevue.co/profile/InvestorsTherapy. Your weekly dose of 3 timeless articles that will make an impact in your life for years to come. Topics include: actionable career advice, free chapters from New York Time's best selling books, interviews with TED speakers, and info on what's going on in the world without the jargon. All of this content is free, but if you would like to support me, feel free to make a donation via patreon at www.patreon.com/jbt

Tweet

Share

If you don't want these updates anymore, please unsubscribe here.

If you were forwarded this newsletter and you like it, you can subscribe here.